Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors
- 1Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece
Abstract
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) regulates necroptotic cell death and sterile inflammation, representing an established therapeutic target for degenerative and inflammatory disorders. Here, three putative hydantoin-based analogues bearing distinctive N-substitutions—an ethylcyclobutyl derivative (Compound 1), an ethoxyphenylethyl analogue (Compound 2), and a 5-chloroindole (3-fluoro-4-methylbenzyl) derivative (Compound 3)—were investigated against the prototypical inhibitor Necrostatin-1 using virtual screening, induced-fit docking, 500 ns molecular dynamics simulations and pharmacokinetic profiling. Induced Fit Docking within the RIPK1 kinase domain indicated that Compound 3 (−9.1 kcal/mol) and Compound 1 (−7.9 kcal/mol) achieved favorable predicted binding scores surpassing Necrostatin-1 (−7.3 kcal/mol), whereas Compound 2 displayed a considerably weaker binding score (−4.1 kcal/mol). All-atom molecular dynamics simulations revealed that Compound 1 maintained high dynamic stability with ligand RMSD constrained to 1.2–2.0 Å and sustained hydrogen bonding with Leu157. Conversely, Compound 2 dissociated from the primary binding pocket, while Compound 3 deviated from its initial docking pose (RMSD 7.0–9.2 Å) to engage a secondary interaction network with Asn170, Glu171 and Lys45. In silico ADME profiling predicted that all three candidates comply with Lipinski and Veber drug-likeness criteria with high predicted intestinal absorption. These computational findings provide putative structural insights into kinase-ligand interactions, prioritizing candidate molecules for chemical synthesis and in vitro biological evaluation.
Related
- Investigating the anticancer potential of phytochemicals from the mangrove Rhizophora mucronata as inhibitors of lung cancer-associated proteins: Insights from multiscale computational and in silico analyses
- Design, Synthesis, and Biological Evaluation of Novel Dithiocarbamate-Based Human Carbonic Anhydrase IX/XII Inhibitors as Potential Anti-Glioblastoma Agents
- Recombinant SIRT1 expression and SIRT1 METTL3 interaction analysis with computational identification of phytochemical SIRT1 activators and inhibitors
- Discovery of natural flavanones as potential PRMT4 inhibitors with antiproliferative activity against colorectal cancer cells
- Steroidogenesis suppression in H295R cells by 1,3-disubstituted ureas: a potential off-target effect of some sEH inhibitors
BibTeX
@article{petsas2026computational,
title = {{Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors}},
author = {Errikos Petsas and Christos T. Chasapis},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219616},
url = {https://www.mdpi.com/1422-0067/27/21/9616},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Computational Evaluation of Necrostatin-1 Analogues as Potential RIPK1 Inhibitors
AU - Errikos Petsas
AU - Christos T. Chasapis
PY - 2026
DA - 2026/10/27
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219616
UR - https://www.mdpi.com/1422-0067/27/21/9616
AB - Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) regulates necroptotic cell death and sterile inflammation, representing an established therapeutic target for degenerative and inflammatory disorders. Here, three putative hydantoin-based analogues bearing distinctive N-substitutions—an ethylcyclobutyl derivative (Compound 1), an ethoxyphenylethyl analogue (Compound 2), and a 5-chloroindole (3-fluoro-4-methylbenzyl) derivative (Compound 3)—were investigated against the prototypical inhibitor Necrostatin-1 using virtual screening, induced-fit docking, 500 ns molecular dynamics simulations and pharmacokinetic profiling. Induced Fit Docking within the RIPK1 kinase domain indicated that Compound 3 (−9.1 kcal/mol) and Compound 1 (−7.9 kcal/mol) achieved favorable predicted binding scores surpassing Necrostatin-1 (−7.3 kcal/mol), whereas Compound 2 displayed a considerably weaker binding score (−4.1 kcal/mol). All-atom molecular dynamics simulations revealed that Compound 1 maintained high dynamic stability with ligand RMSD constrained to 1.2–2.0 Å and sustained hydrogen bonding with Leu157. Conversely, Compound 2 dissociated from the primary binding pocket, while Compound 3 deviated from its initial docking pose (RMSD 7.0–9.2 Å) to engage a secondary interaction network with Asn170, Glu171 and Lys45. In silico ADME profiling predicted that all three candidates comply with Lipinski and Veber drug-likeness criteria with high predicted intestinal absorption. These computational findings provide putative structural insights into kinase-ligand interactions, prioritizing candidate molecules for chemical synthesis and in vitro biological evaluation.
SN - 1422-0067
ER -